Longevity Biomedical (Longevity Biomedical) Change In Receivables : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Change In Receivables?

Longevity Biomedical's change in receivables for the quarter that ended in . 20 was $0.00 Mil. It means Longevity Biomedical's Accounts Receivable stayed the same from . 20 to . 20 .

Longevity Biomedical's change in receivables for the fiscal year that ended in . 20 was $0.00 Mil. It means Longevity Biomedical's Accounts Receivable stayed the same from . 20 to . 20 .

Longevity Biomedical's Accounts Receivable for the quarter that ended in . 20 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Longevity Biomedical's liquidation value for the six months ended in . 20 was $0.00 Mil.

Longevity Biomedical Change In Receivables Historical Data

The historical data trend for Longevity Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Change In Receivables Chart

Longevity Biomedical Annual Data

Trend

Change In Receivables

Longevity Biomedical Semi-Annual Data

Change In Receivables

Longevity Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Longevity Biomedical (NAS:LBIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Longevity Biomedical's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Longevity Biomedical's accounts receivable are only considered to be worth 75% of book value:

Longevity Biomedical's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Longevity Biomedical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines